Apellis and Sobi land another late-stage win for rare kidney disease drug
Empaveli, the kidney disease drug from Apellis Pharmaceuticals and Sobi, reported a Phase 3 trial success that could help the treatment keep pace with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
